<DOC>
	<DOCNO>NCT00504426</DOCNO>
	<brief_summary>The purpose study examine efficacy safety OPC-249 daily inhalation 0 ( placebo ) , 30 , 60 120 IU 4 week patient pain due osteoporosis .</brief_summary>
	<brief_title>Dose-ranging Trial OPC-249 Powder Inhalation Patients With Pain Due Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>Patients fulfill follow item Patients primary osteoporosis Patients exist 14 vertebral fracture Patients back pain persist one week Postmenopausal woman 46 less 80 year age</criteria>
	<gender>Female</gender>
	<minimum_age>46 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>